Home » Stocks » BDSI

BioDelivery Sciences International, Inc. (BDSI)

Stock Price: $4.43 USD 0.21 (4.85%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $4.49 +0.06 (1.35%) Feb 24, 7:30 PM
Market Cap 442.19M
Revenue (ttm) 145.94M
Net Income (ttm) 14.82M
Shares Out 101.03M
EPS (ttm) 0.15
PE Ratio 28.95
Forward PE 10.09
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $4.43
Previous Close $4.23
Change ($) 0.21
Change (%) 4.85%
Day's Open 4.22
Day's Range 4.18 - 4.47
Day's Volume 1,031,429
52-Week Range 2.85 - 5.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT

Investopedia - 2 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BMRN, CPRX, INVA, NVAX, VRTX, VXRT, VYGR
Zacks Investment Research - 2 months ago

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 3 months ago

RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...

Zacks Investment Research - 3 months ago

Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

GlobeNewsWire - 3 months ago

RALEIGH, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...

Seeking Alpha - 3 months ago

BioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Total Company Net Revenue Increased 30% versus Prior Year Reaching a Record $39.4 Million

GlobeNewsWire - 3 months ago

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...

GlobeNewsWire - 3 months ago

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...

GlobeNewsWire - 4 months ago

RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...

GuruFocus - 4 months ago

Investors who target growth may want to consider investing in the following small-cap stocks as they represent companies whose trailing 12-month pro forma earnings per share advanced significa...

Other stocks mentioned: ATEN, MITK
GlobeNewsWire - 5 months ago

New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) New Scientific Information Further Highlights Differentiated Clinical Prof...

Zacks Investment Research - 5 months ago

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 5 months ago

My Pound The Table Moment For BioDelivery Sciences

GlobeNewsWire - 5 months ago

RALEIGH, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living wit...

Zacks Investment Research - 6 months ago

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.

Seeking Alpha - 6 months ago

BioDelivery Sciences International, Inc. (BDSI) Management on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

BioDelivery (BDSI) delivered earnings and revenue surprises of -75.00% and 0.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million

Zacks Investment Research - 6 months ago

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, BNFT, CLRB, LNT
GlobeNewsWire - 6 months ago

RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...

Seeking Alpha - 7 months ago

BioDelivery Sciences: Fundamentals Continue Divergence From Share Price

Zacks Investment Research - 8 months ago

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 9 months ago

RALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...

Seeking Alpha - 9 months ago

BioDelivery Sciences: Undervalued $5 Biopharma Still Growing Despite COVID-19

Zacks Investment Research - 9 months ago

BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues.

Seeking Alpha - 9 months ago

BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 10 months ago

Keep your eyes on these two stocks in the months to come.

Other stocks mentioned: TRIL
Seeking Alpha - 10 months ago

BioDelivery Sciences Strong As Ever But At Half The Price

Seeking Alpha - 11 months ago

Bully For BioDelivery Sciences

Zacks Investment Research - 11 months ago

BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.

Seeking Alpha - 11 months ago

BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

BioDelivery (BDSI) delivered earnings and revenue surprises of 700.00% and 4.98%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 11 months ago

Mr. Bailey Further Strengthens Company Leadership Bringing more than 30 Years of Significant Industry Experience including Commercial Operations and Board Management Mr. Bailey Further Strengt...

GlobeNewsWire - 11 months ago

BELBUCA® Effect on Respiratory Drive was Comparable to Placebo in Clinical Trial at all Tested Doses

Seeking Alpha - 1 year ago

Fantastic Buying Opportunity For BDSI

Zacks Investment Research - 1 year ago

Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.

InvestorPlace - 1 year ago

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

Other stocks mentioned: ATEC, BTAI, FOLD, GERN, INO, INSM
Zacks Investment Research - 1 year ago

BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 1 year ago

RALEIGH, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...

Seeking Alpha - 1 year ago

BioDelivery Sciences: Still Some Upside

Zacks Investment Research - 1 year ago

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 1 year ago

RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to pat...

Zacks Investment Research - 1 year ago

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 year ago

Selecting breakout stocks continues to be one of the most popular methods utilized by active investors.

Other stocks mentioned: AIRI, HALL, VGR

About BDSI

BioDelivery Sciences International, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to trea... [Read more...]

Industry
Biotechnology
Founded
1997
CEO
Jeffrey Bailey
Employees
178
Stock Exchange
NASDAQ
Ticker Symbol
BDSI
Full Company Profile

Financial Performance

In 2019, BDSI's revenue was $111.39 million, an increase of 100.20% compared to the previous year's $55.64 million. Losses were -$15.31 million, -54.81% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BDSI stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 80.59% from the latest price.

Price Target
$8.00
(80.59% upside)
Analyst Consensus: Strong Buy